半胱天冬酶募集结构域蛋白6通过抑制凋亡信号调节激酶1保护小鼠抵抗肝脏脂肪变性和胰岛素抵抗
在非酒精性脂肪性肝病(NAFLD)患者、肥胖小鼠及棕榈酸处理的肝细胞模型中,Card6表达下调与脂肪肝密切相关。Card6功能获得和缺失小鼠模型表明,Card6通过抑制Ask1及其下游JNK/p38信号,保护小鼠抵抗高脂饮食诱导的胰岛素抵抗、肝脏脂肪变性和炎症反应。腺病毒介导的肝脏Card6过表达可改善ob/ob小鼠的胰岛素抵抗和肝脏脂肪变性。
要点
- NAFLD患者、肥胖小鼠及棕榈酸处理肝细胞中Card6表达下调。
- Card6通过抑制Ask1及下游JNK/p38信号保护小鼠抵抗高脂饮食诱导的肝脏脂肪变性和胰岛素抵抗。
- 肝脏过表达Card6可改善ob/ob小鼠的胰岛素抵抗和肝脏脂肪变性。
核心结论
- Card6是NAFLD中重要的负性调控因子,作者认为以Card6靶向Ask1可能是开发NAFLD治疗方法的良好策略。
研究设计与样本
- 研究检测了NAFLD患者、肥胖小鼠及棕榈酸处理的肝细胞模型中Card6的表达,并利用Card6功能获得和缺失小鼠模型以及腺病毒介导的肝脏Card6过表达ob/ob小鼠进行机制和功能验证。
主要发现
- Card6下调与NAFLD患者、肥胖小鼠及棕榈酸处理肝细胞模型中的脂肪肝密切相关。
- Card6功能获得和缺失小鼠模型显示,Card6在高脂饮食给药后保护小鼠抵抗胰岛素抵抗、肝脏脂肪变性和炎症反应。
- 机制上,Card6与Ask1相互作用并抑制Ask1及其下游c-Jun N端激酶/p38信号。
- Ask1足以介导Card6功能,且Ask1与Card6之间的相互作用对Card6体内功能绝对必需。
- 腺病毒介导的肝脏Card6过表达有效改善ob/ob小鼠的胰岛素抵抗和肝脏脂肪变性。
临床怎么用
- 原文结论指出,以Card6靶向Ask1可能是开发NAFLD治疗方法的良好策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The rapidly increasing prevalence of metabolic disorders associated with nonalcoholic fatty liver disease (NAFLD) warrants further study of the underlying mechanisms to identify key regulators as targets for the development of therapeutic interventions. Caspase recruitment domain protein 6 (Card6), as a member of the CARD family that regulates cell death and immunity, may potentially control this process. Indeed, Card6 down-regulation was found to be closely associated with the fatty livers observed in NAFLD patients, obese mice, and a palmitate-treated hepatocyte model. Gain-of-function and loss-of-function Card6 mouse models demonstrated that Card6 protected mice from insulin resistance, hepatic steatosis, and inflammatory responses upon high-fat diet administration. Mechanistically, Card6 interacted with and inhibited apoptosis signal-regulating kinase 1 (Ask1) and its subsequent downstream c-Jun N-terminal kinase/p38 signaling. Furthermore, Ask1 was sufficient to mediate Card6 function, and the interaction between Ask1 and Card6 was absolutely required for Card6 function in vivo. Adenovirus-mediated Card6 overexpression in the liver effectively ameliorated insulin resistance and hepatic steatosis in ob/ob mice. Therefore, we identified Card6 as an important negative regulator in NAFLD. Conclusion: Targeting Ask1 by Card6 may be a good strategy to develop a therapeutic method against NAFLD.
引用
- Sun P, Zeng Q, Cheng D, et al. Caspase Recruitment Domain Protein 6 Protects Against Hepatic Steatosis and Insulin Resistance by Suppressing Apoptosis Signal-Regulating Kinase 1. Hepatology. 2018. PMID: 29729191. doi:10.1002/hep.30075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。